Signaling in Myocardial Hypertrophy Life After Calcineurin?
Peter H. Sugden C ardiac (ventricular) hypertrophy is an important adaptive response in vivo that (at least in the shorter term) allows the organism to maintain or increase its cardiac output. Global ventricular hypertrophy is a recognized response to increased pressure or volume work (reviewed in Reference 1), with increased myofibrillogenesis and sarcomere deposition being cardinal features. Although global hypertrophy is clinically important, probably the most significant form of cardiac hypertrophy in terms of patient numbers is the localized hypertrophy of the ventricular wall that may follow loss of myocardium after a survivable myocardial infarct. In the early stages, both global and localized hypertrophy may resemble the readily reversible, nonfibrotic "physiological" hypertrophy that develops after repeated endurance exercise. In the longer term, beneficial, "compensated" hypertrophy may decay into maladaptive "decompensated" hypertrophy and heart failure (reviewed in References 2 and 3) with diminished coronary flow reserve and increased risk of lethal arrhythmias. Although some aspects of the maladapted state are probably intrinsic to the myocyte [eg, prolongation of the action potential and Ca 2ϩ transient (reviewed in References 4 and 5)], other factors (increased fibrosis and mismatch between O 2 supply and demand) are also probably involved in decompensation.
The predominating view is that mammalian ventricular myocytes lose their capacity for cell division during the perinatal period and are thus terminally differentiated cells, although this is still a matter of some dispute (reviewed in References 6 and 7). In contrast, other cells in the heart (endothelial cells, fibroblasts, and smooth muscle cells) retain their mitotic capacity. Although ventricular myocytes are not the only cell type involved in the overall hypertrophic response, much of the ventricular enlargement or remodeling is attributable to their hypertrophy. The identities of signaling pathways that couple the demand for increased contractile power to increased myocyte growth and altered gene expression have been actively investigated for many years. Protein phosphorylation (catalyzed principally by Ser-/Thr-or Tyrspecific protein kinases) and phosphoprotein dephosphorylation (catalyzed by phosphoprotein phosphatases) play central roles in the regulation of many cellular events, including growth and cell division, and it is widely believed that these processes participate in myocyte hypertrophy.
From the broad point of view, 2 hypotheses of hypertrophy have been proposed, which are the extrinsic and the intrinsic hypotheses. The former maintains that myocyte hypertrophy results from extracellular factors ( Table 1 ) that are either of a neuroendocrine origin (eg, the catecholamines) or are synthesized and released locally by the myocytes and nonmyocytes in the heart (eg, endothelin-1 [ET-1] and angiotensin II [Ang II]). The intrinsic hypothesis maintains that changes originating within the myocyte are responsible for hypertrophy. Because of its well-established role in excitation-contraction coupling, increased [Ca 2ϩ ] i concentration has been suggested to be an intrinsic mediator. The 2 hypotheses are not mutually exclusive because, in the hands of some workers, extrinsic agonists such as ET-1 increase [Ca 2ϩ ] i concentrations in myocytes (reviewed in References 8 and 9) and, conversely, [Ca 2ϩ ] i is known to be involved in the secretion of peptide hormones (eg, secretion of atrial natriuretic factor [ANF] from myocytes 10 ). The problem with the Ca 2ϩ hypothesis is that, although [Ca 2ϩ ] i has been implicated in the hypertrophic response, 11, 12 no clearly defined coupling mechanism has been substantiated until recently. As discussed in the accompanying article, 13 the recent elegant studies of Molkentin et al 14 have provided evidence that the Ca 2ϩ /calmodulin (CaM)-dependent phosphoprotein phosphatase calcineurin (also known as protein phosphatase 2B) plays a significant role in myocyte hypertrophy. The excitement generated by this finding was demonstrated by the rapid appearance of editorials in Science 15 and Nature Medicine. 16 The problem is that there will be an inevitable temptation to believe that the biochemical mechanisms underlying myocyte hypertrophy and heart failure have been elucidated in all but detail and that therapeutic intervention is now readily at hand. Indeed, in a review of a recent manuscript that we submitted, one reviewer made the following comment: "The authors talk a lot about the mitogen-activated protein kinase (MAPK) pathway and hypertrophy and omit any mention of the recent and exciting observations about the role of Ca 2ϩ and calcineurindependent activation of NFAT [nuclear factor of activated T lymphocytes] transcription factors in hypertrophy. At this point, it seems likely that many of the hypertrophic effects of the agonists used here are mediated by the calcineurin-NFAT pathway rather than the MAPK pathway." In my opinion, this comment crystallizes the dangers that Molkentin et al 14 have unintentionally created, and I am convinced that the issue is far from settled. There are 3 main points that I wish to cover. First, is there evidence for the involvement of other (possibly interacting) signaling pathways leading to hypertrophy? Second, how convincing is the evidence for involvement of calcineurin? Third, if calcineurin is involved, how convincing is the mechanism proposed by Molkentin et al, 14 namely dephosphorylation of the transcription factor nuclear factor of activated T-lymphocytes-3 (NFAT3)?
Experimental Investigation of Myocardial Hypertrophy

Hypertrophy in Vitro
The most commonly used in vitro model involves primary culture of neonatal rat ventricular myocytes, and this has allowed the biochemical and molecular characteristics of hypertrophy to be studied in detail under controlled conditions (reviewed in References 17 through 19). A plethora of hypertrophic factors and interventions has been identified (Table 1) . It is invidious to attempt to identify a single hypertrophic agonist, and many may participate in vivo. Although there is concern about the fidelity of simulation of the adult hypertrophic response, many of the changes seen in the cultured neonatal cells have also been detected in adult animals in vivo (reviewed in Reference 17). When exposed to hypertrophic stimuli, myocytes in culture show increased myofibrillogenesis, and the cells enlarge. From a biological standpoint, accumulation of sarcomeres is perhaps the most important feature of cardiac hypertrophy, because, above all other manifestations, this allows the myocyte to increase its contractile power. In addition, there are alterations (both upregulation and downregulation) in gene expression. Immediate-early genes that encode transcription factors (c-fos, c-jun, and Egr-1) are rapidly (within 1 hour) and transiently upregulated, and these may be important in the regulation of genes encoding myofibrillar proteins. B-type natriuretic peptide (BNP) is expressed at this early stage, and this is maintained. 20 In the medium term (12 to 24 hours), the "fetal" pattern of gene expression is recapitulated with reexpression of ANF, skeletal muscle ␣-actin, and ␤-myosin heavy chain (␤-MHC Gene expression is regulated by the binding of trans-acting transcription factors and other cooperating proteins (eg, RNA polymerases) to cis-acting consensus recognition sequences that lie upstream (5Ј) from the transcriptional initiation sites in genes (the promoter region) or to more distant enhancer regions. For most genes, these regions contain multiple sequences recognized by a variety of transcription factors (for a review on the heart, see Reference 22) , and interactions between the various DNA-bound transcription factors occur. Gene expression is most commonly studied by transient transfection of expression plasmids containing fusion genes of the 5Ј-upstream regulatory sequences of hypertrophic "marker" genes (eg, ANF) coupled to suitable reporter genes. This has allowed the identification of regulatory elements within the promoter regions. By cotransfecting/coinfecting suitable reporters with plasmids or adenoviral vectors encoding signaling proteins, this approach has been used to identify putative participants in the induction of hypertrophy.
One frequently ignored fact is that hypertrophy requires increased accumulation of protein (particularly of myofibrillar proteins) and increased myofibrillogenesis. Control at the level of protein turnover and sarcomeric assembly is necessary. As reviewed in Reference 19, hypertrophic agonists generally increase the rate of protein synthesis in the short term by increasing the peptide chain initiation (the ratecontrolling step). In the longer term, ribosomal synthesis also increases. Because of the experimental difficulties in measuring protein degradation (particularly of specific proteins) with accuracy, it is not clear whether this process is also regulated. In addition, the regulation of myofibrillogenesis is also poorly understood.
Hypertrophy In Vivo
In vivo, probably the most commonly used surgical intervention involves coarctation of the aorta, which induces a pressure-overload hypertrophy. It is important to note that although the aorta can be coarcted at a variety of levels to induce pressure overload, the models may not be necessarily equivalent. 23 A variety of transgenic mouse models of cardiac (see also Table 2 ). Since we have reviewed this topic in depth recently, 19, 31, 32 only the salient features will be outlined. I do not wish to exclude involvement of other protein kinases (eg, the Janus kinases, [33] [34] [35] Ca 2ϩ /CaM kinase II, 36 and most recently myosin light chain kinase, 37 ), but work on these has been less extensive. MAPK cascades consist of 3-member protein kinase "modules" (Figure 1 ). The MAPK kinase kinases (MKKKs) are Ser-/Thr-specific kinases that phosphorylate and activate MAPK kinases (MKKs), and the MKKs in turn phosphorylate and activate the MAPKs, the cascade thus allowing signal integration and amplification. MAPKs are unusual in that they require phosphorylation of a Tyr and a Thr residue in a Thr-Xaa-Tyr motif that lies on their surface in a regulatory loop of varying length, and the sequence of this tripeptide represents 1 criterion for MAPK classification. After their activation, MAPKs phosphorylate a broad range of substrates (including nuclear transcription factors, other protein kinases, and various signaling molecules), thereby modifying their biological activities. Although MAPKs preferentially phosphorylate (Ser/Thr)-Pro sequences (or, even better, Pro-Xaa-[Ser/Thr]-Pro 38 ; reviewed in Reference 39), this dipeptidyl sequence is relatively common in proteins, and other factors also contribute to specificity (reviewed in Reference 40).
GTP-binding proteins (G proteins) participate in the activation of MAPK cascades, and these can be broadly divided into 2 types: the heterotrimeric (GPCR-associated) group and the p21 small G protein superfamily, of which there are 5 subgroups (prototypically Ras, but also Rho, ADP ribosylation factors, Rab, and Ran). Of the heterotrimeric G proteins, the G q /G 11 subfamily (G q for simplicity) has been shown most convincingly to be associated with hypertrophy. From the p21 small G protein superfamily, only the Ras and Rho subgroups (reviewed in References 41 and 42, respectively) have been examined from this standpoint. All G proteins are biologically inactive in their GDP-ligated form and become activated on exchange of GDP for GTP. Their innate GTPase activity returns them to the inactive state (the GDP/GTP cycle), but this process can be stimulated by ancillary proteins. A number of proteins also affect GDP/GTP exchange (the GPCRs in the case of heterotrimeric G proteins, stimulatory guanine nucleotide exchange factors such as Sos, and inhibitory factors for the small G proteins).
I will use ET-1 as my principal example of a hypertrophic GPCR agonist, as there is unanimity that it is strongly hypertrophic. By binding to heptahelical transmembrane GPCRs, agonists such as ET-1 stimulate the dissociation of membrane-bound inactive heterotrimeric G q proteins [(␣ q ⅐ GDP) ⅐ ␤␥] into ␣ q ⅐ GTP and ␤␥ dimers. Both ␣ q ⅐ GTP and ␤␥ dimers are potentially capable of activating phospholipase C␤ isoforms leading to the hydrolysis of membrane phosphatidylinositol 4,5-bisphosphate (PtdInsP 2 ) to inositol 1,4,5-trisphosphate (InsP 3 ) and diacylglycerols (DGs). DGs are retained in the plane of the membrane, and the DG-sensitive isoforms of PKC (principally nPKC␦ and nPKC⑀ in the rat ventricular myocyte 43, 44 ) translocate to the particulate fraction (and presumably become activated). Phorbol esters such as phorbol 12-myristate 13-acetate (PMA) act as DG analogs and also translocate myocytic nPKC␦ and nPKC⑀, 45, 46 and they are also strongly hypertrophic. 47, 48 The next step(s) in the signaling pathway is unclear, but the end result is that both ET-1 and PMA activate membrane-bound Ras (Ras ⅐ GDP3 Ras ⅐ GTP) (A. Chiloeches, P.H. Sugden, unpublished data, 1998).
One of the best-defined roles of Ras ⅐ GTP is its activation of the extracellular signal-regulated protein kinase (ERK) cascade (Figure 1) , which is particularly involved in cell growth, division, and differentiation. The ERK cascade MKKKs are members of the Raf family (c-Raf, A-Raf, and B-Raf), the MKKs are MKK1 and MKK2, and the MAPKs (phosphorylation motif Tyr-Glu-Thr) are ERK1 (p44-MAPK) and ERK2 (p42-MAPK). ET-1 and PMA strongly activate all 3 stages of the ERK cascade (Raf, 49 MKK1 and -2, 50 and ERKs 43, 50, 51 ) in myocytes. Activation of Raf involves its binding to membrane-localized Ras ⅐ GTP and its translocation to this fraction. It is not clear whether this interaction is sufficient to activate Raf or whether other events such as Ser/Thr phosphorylation and/or Tyr phosphorylation (possibly involving nonreceptor protein Tyr kinases of the Src family 52, 53 ) are additionally required. The potential for ERKs to regulate gene transcription in the myocyte is demonstrated by the rapid appearance (within 4 minutes) of active phosphoERKs in nuclei of myocytes exposed to PMA (H.F. Paterson, P.H. Sugden, unpublished data, 1998).
Depending on the criteria used, there are an additional 2 (see, eg, Reference 32) or 5 (see, eg, Reference 54) subgroups of the MAPK superfamily. The simpler classification based on the sequences of the tripeptide phosphorylation motif will be used here. The c-Jun N-terminal kinases (JNKs; phosphorylation motif Thr-Pro-Tyr) and the p38-MAPKs (phosphorylation motif Thr-Gly-Tyr) were first identified as being activated by cellular stresses (eg, protein synthesis inhibitors, hyperosmotic shock, and reactive oxygen species), and this is certainly true in myocytes. [55] [56] [57] It has also emerged that G q protein-coupled receptor (G q PCR) agonists such as ET-1 are moderately effective in activating JNKs 55 and p38-MAPK 57 in these cells but that PMA is a poor activator. 55, 57 The upstream signaling pathways are not as clear as in the ERK cascade, although MKKs, MKKKs, other protein kinases, and small G proteins (particularly Rac and Cdc42, 2 members of the Rho subfamily) are likely to be involved. As with the ERKs, activation of JNKs and p38-MAPKs leads to phosphorylation of transcription factors ( Figure 1 ) and other signaling molecules. Generally speaking, the biological roles of the JNKs and p38-MAPKs are less clear than those of the ERKs. In addition to their hypertrophic actions in myocytes (Table 2) , activation of JNKs has been associated with apoptosis in nonmyocytes and myocytes, 58, 59 whereas the p38-MAPKs have been associated with both apoptosis 60 and cytoprotection/cell survival 57, 59, 61 in myocytes (and other cells).
There is considerable evidence that activation of any of the 3 MAPK cascades can lead to a hypertrophic response in myocytes. All 3 MAPK subfamilies are activated by ET-1 and other hypertrophic GPCR agonists, 43, 50, 51, 55, 57 and the novel hypertrophic agonist prostaglandin F 2␣ 62,63 has recently been shown to activate JNKs. 64 Transfection/infection of suitably constitutively activated components of the cascades (Table 2 ) leads to induction of many features of the hypertrophic response, although myofibrillogenesis is not always observed. Transfection/infection of "dominant-negative" (inhibitory) mutant components of the cascades opposes the hypertrophic actions of GPCR agonists, as does downregulation of ERKs by antisense oligodeoxynucleotides 65 or transfection of phospho-MAPK phosphatases. 66, 67 It is evident from Table 2 that there is still considerable confusion in this area, and the reasons for the variations between experimental groups are unclear (reviewed in Reference 32). Two points should be borne in mind. First, the degree of overexpression may mean that the experiments have little relation to the physiological situation. Second, the regulation of transcription from genomic DNA may be quite different from that from episomal (plasmid) DNA because of the influence of chromatin proteins. In the hands of some (but not all 68, 69 ) investigators, selective inhibitors of the ERK and p38-MAPK cascades (PD98059 for the ERK cascade 57 and SB203580 or SB202190 for the p38-MAPK cascade 60, 61, 70 ) diminish the hypertrophic response to GPCR agonists, although the interpretation of these studies may not be simple. 57 The overall conclusion is that MAPK cascades participate in the hypertrophic response. The ensuing steps are unclear, but it is presumed that transcription factor phosphorylation and transcriptional activation follow, and ET-1 certainly induces phosphorylation and upregulation of c-Jun protein in myocytes. 71 Furthermore, the interaction of the novel transcription factor ATF6 with the ANF promoter region, which may be responsible for inducible expression of ANF, may be stimulated by p38-MAPK-dependent phosphorylation of ATF6. 72 Despite some anomalies, 66, 68, 73 I personally still favor a predominating role for the ERKs, and I regard the hypertrophic response as an attempt at "transformation" in a terminally differentiated cell.
In addition, activation of participating signaling molecules proximal to the MAPK cascades leads to a hypertrophic phenotype. With particular reference to the ERK cascade, it is clear that transient transfection of myocytes with constitutively activated forms of the G␣ q subunit, 69, 74 PKC isoforms, [75] [76] [77] Ras, 78 or Src 79, 80 leads to a hypertrophic response. Inhibition of G␣ q signaling in transgenic mice by disruption of coupling between the G q PCR and G q protein diminishes the hypertrophy associated with pressure overload and diminishes the activation of ERKs by G q PCR agonists. 81 Except for Src (which has not been tested), cardiospecific overexpression of each of these signaling molecules leads to the development of cardiac hypertrophy and heart failure in transgenic mouse models, 30, [82] [83] [84] [85] [86] although some investigators have interpreted their results as indicating that the hypertrophy is independent of ERKs (see, eg, Reference 84). One problem with this interpretation is that ERK was only examined at the heart failure end stage. Activation of ERKs by hypertrophic agonists is transient, 50 and they probably trigger responses. Prolonged activation would therefore not be anticipated.
Participation of the Rho family of small G proteins (Rho isoforms themselves [eg, RhoA], Rac, and Cdc42, reviewed in Reference 42) in hypertrophy has also been examined. In a variety of nonmyocytic cell lines, the Rho family regulates cell morphology and actin stress fiber assembly. In addition, Rac and Cdc42 appear to be involved in activation of the JNK and p38-MAPK cascades, but Rho isoforms are not thought to activate these cascades. Although less effective than constitutively activated Ras, constitutively activated Rac is hypertrophic. 70 Signaling through Rho itself is poorly understood. Two groups of Rho-activated protein kinases (Rho kinase/ROK␣ and PRK/PKN groups) have been identified (reviewed in Reference 87), the PRK/PKN group being related to PKC (reviewed in Reference 88). Recent evidence suggests that, in addition to Ras, hypertrophy induced by or mediated through G␣ q may also require signaling through RhoA 69,89 -92 and that Rho kinase/ROK␣ may mediate this effect. 92 However, it is not clear whether hypertrophic agonists activate Rho or the various Rho-dependent kinases.
An Involvement of Calcineurin in Myocardial
Hypertrophy and Heart Failure?
Calcineurin (reviewed in References 93 and 94) is a ubiquitously expressed phosphatase that is activated by micromolar Ca 2ϩ concentrations. It is a heterodimer of a 60-to 65-kDa calcineurin A subunit and a 19-kDa calcineurin B subunit. All calcineurin A isoforms contain N-terminal and C-terminal variable domains, a catalytic domain, and a regulatory domain. The regulatory domain contains a calcineurin B-binding helix, a CaM-binding domain, and an autoinhibitory region that binds to the active site preventing enzymic activity at low Ca 2ϩ concentrations. A constitutively activated mutant calcineurin A (calcineurin A[13398]) has been described in which about two thirds of the N-terminal region of the regulatory domain has been deleted. 95 The deleted region includes most of the CaM-binding domain, the autoinhibitory domain, and the C-terminal variable region, but the calcineurin B and immunophilin (see below) binding sites are intact. Increasing the Ca 2ϩ concentration into the micromolar range causes a small activation in the absence of CaM, but in the presence of CaM, there is a highly cooperative activation of calcineurin. The role of calcineurin B in the regulation of enzymic activity by Ca 2ϩ is obscure. It is essential for enzymic activity (perhaps more so than CaM), but the suggestion is that it fulfils a structural role.
One exciting function of calcineurin is its involvement in NFAT-mediated T-lymphocyte activation (reviewed in References 94, 96, and 97). NFATs (reviewed in References 94 and 97) are a family of Rel homology transcription factors, a group that also includes nuclear factor B. In the inactive state, NFATs are phosphorylated and (like nuclear factor B) are retained in the cytoplasm. NFATs are tightly associated with calcineurin, and this association is apparently independent of the phosphorylation state of NFAT. When T lymphocytes bind to antigen-presenting cells through T-lymphocyte receptors, cytoplasmic Ca 2ϩ concentrations increase and activate calcineurin, leading to NFAT dephosphorylation (Figure 2) . This allows NFAT to migrate into the nucleus (still complexed to calcineurin 98 ), where it upregulates the transcription of a number of genes, including those for interleukin-2 (an autocrine growth factor in T lymphocytes) and other lymphocyte growth factors. The increase in cytoplasmic Ca 2ϩ is mediated by phospholipase C␥-catalyzed hydrolysis of PtdInsP 2 to InsP 3 , with concomitant release of Ca 2ϩ from intracellular stores. In addition, muscarinic G q PCR-mediated activation of NFATs has been described in lymphocytes and other cells. 99, 100 It is not clear which protein kinases maintain NFAT in its inactive state in the cytoplasm in any cell type, and this remains an important question. Candidates include JNKs, 101 casein kinase I␣ in conjunction with MAPK/ERK kinase kinase (MEKK1, an MKKK), 102 and glycogen synthase kinase 3. 103, 104 Calcineurin is the target of the immunosuppressants cyclosporin A (CsA) and FK-506 in T lymphocytes (reviewed in References 94 and 97). These bind to their respective binding proteins, the immunophilins cyclophilin A and 12-and 12.6-kDa FK-506 binding proteins (FKBP12 and FKBP12.6, respectively). The CsA-cyclophilin and FK506-FKBP12 complexes bind to the calcineurin heterodimer and prevent its activation. In T cells, CsA inhibits the activation of the JNK and p38-MAPK cascades by an unknown mechanism. 105 This observation may be relevant to hypertrophy, in which (as described above) both of these cascades have been implicated.
Calcineurin and Cardiac Hypertrophy/Heart Failure
The transcription factor GATA4 106 (reviewed in Reference 107) is present in adult heart (and a limited number of other tissues) and is involved in the positive regulation of a variety of hypertrophic marker genes, including ANF, BNP, and ␤-MHC. 108,109 GATA4 interacts with other transcription factors, and recent work has suggested that ANF expression may be regulated by cooperative interaction of cis elements with GATA4 and Csx/Nkx2.5. 110 Csx/Nkx2.5 is a homeodomain transcription factor that is cardiospecifically expressed into adulthood. 111, 112 The recent findings of Molkentin et al 14 (summarized in Reference 13) implicating a [Ca 2ϩ ] i 3calcineurin3 NFAT3 pathway in cardiac hypertrophy that is analogous to T-cell activation have caused a great deal of excitement. Using a yeast 2-hybrid screen and a mouse whole-embryo cDNA library, numerous clones encoding proteins interacting with GATA4 were isolated. The only clone of which the identity was reported encoded NFAT3, and details of the identities of the other proteins are eagerly awaited. However, given that a whole embryo library was used, these species may not be relevant to the heart. Myocytes transiently transfected with plasmids encoding calcineurin A(13398), NFAT3, and GATA4 dramatically increased expression of a BNP reporter. Transfection of any 1 plasmid, or of any 2 plasmids, was much less effective. It is somewhat surprising that calcineurin A(13398) alone did not stimulate the BNP reporter, and this might suggest that NFAT3 and/or GATA4 are limiting. The expression of ANF and cardiac troponin I genes was examined, but no quantitative details were presented. It is not clear whether myofibrillar assembly was increased in the transfected myocytes. CsA or FK-506 reduced the increases in cell size and myofibrillar assembly of myocytes exposed to Ang II or phenylephrine for 72 hours, as well as the Ang II-induced increase in ANF mRNA expression. This result appears to differ from that of Boluyt et al, 113 who showed that FK-506 was ineffective in reducing phenylephrine-induced increases in myocyte size.
Molkentin et al 14 suggested that Ang II and phenylephrine (and, inferentially, ET-1) increase [Ca 2ϩ ] i concentrations, and indeed some workers have found this to be the case. This is by no means universally accepted, especially in adult cardiac myocytes. 114 -116 However, there is good evidence that these agonists induce alkalosis in myocytes (reviewed in References 9, 117, and 118) probably by activating the sarcolemmal Na ϩ /H ϩ exchanger (reviewed in Reference 119), a process known to be regulated by PKCs and MAPKs. Given that Ca 2ϩ binding to regulatory "EF hands" proteins such as CaM and troponin C is mediated by deprotonated acidic amino acids, 120 Figure 2 ). This is rather a satisfying hypothesis from another point of view, because small increases in pH i potently stimulate cardiac protein synthesis, 123 another cardinal feature of the hypertrophic response. Myocardial hypertrophy could be mediated through changes in the concentrations of simple ions (Ca 2ϩ and H ϩ ).
Transgenic Mice
Cardiomyocytic (␣-MHC promoter-controlled) expression of calcineurin A(13398) in a number of founder lines induced a cardiac enlargement viewed by the authors as corresponding principally to "concentric" hypertrophy, 14 the 125 This is quite different from the situation in the mouse heart, in which the rate of beating is Ϸ400 per 1 minute. It is not clear whether such rapid transients lead to activation of calcineurin, and, unfortunately, it is not feasible to measure calcineurin activity in situ. Nor is it clear to what extent the myocardial hypertrophy and failure in these transgenic animals represents an accurate analog of the human disease, given the possible disturbances in development that could occur because of "leaky" ␣-MHC promoter activation (see above) with activation of calcineurin during embryogenesis and fetal life. Furthermore, it is not known whether pure myocyte hypertrophy alone contributed to the cardiac enlargement, or whether there was coexisting myocyte hyperplasia, as seen in transgenic mice that overexpress CaM developmentally. 126 It is interesting that myocytes from calcineurin A(13398) transgenic animals showed alterations in nuclear morphology, 14 suggesting that the protein may interfere with the cell cycle.
Cardiospecific expression of constitutively activated NFAT3 (NFAT3⌬317, in which the N-terminal third of the molecule encompassing the sites of phosphorylation and calcineurin interaction is deleted) caused hypertrophy in transgenic mice. 14 In cultured myocytes, NFAT3⌬317 protein was localized to the nucleus, whereas the full-length protein remained in the cytoplasm. To my mind, this represents some of the strongest evidence that the calcineurin/NFAT3 pathway induces myocardial hypertrophy. However, it is not clear whether hearts from the NFAT3⌬317 transgenic mice were similar to those from calcineurin A(13398) transgenic animals, nor whether transfection of NFAT3⌬317 induced a hypertrophic phenotype in cultured myocytes. Again, the possible involvement of NFAT in cardiac development 127 should be borne in mind.
Interaction of Calcineurin, Ca 2؉ , and MAPK Signaling Pathways
There is clear evidence that the calcineurin/NFAT pathway interacts with other signaling pathways. In the nucleus, NFATs interact with the activator protein-1 (AP-1) transcription factor complex (c-Fos/c-Jun heterodimers) to bind to the 5Ј-regulatory region of the interleukin-2 gene (reviewed in References 96 and 128), and the crystal structure of this complex has recently been determined. 129 Since AP-1 transactivating activity is under the control of signals emerging from the Ras superfamily and the MAPK cascades (eg, through phosphorylation of c-Jun, reviewed in References 130 and 131), these signaling pathways cooperate with the calcineurin pathway (reviewed in References 128 and 132). Although currently there is no experimental evidence to suggest the existence of regulatory interaction, the promoter region of the ANF gene contains 2 AP-1-related cAMP responsive element (CRE)-like consensus sequences (TGAGCTCA, at -555 to -549 bp and at -603 to -596 bp on the sense strand) in close apposition to 2 NFAT sequences (consensus [A/T]GGAAA, at -541 to -536 bp on the sense strand and at -612 to -607 bp on the antisense strand). The CRE-like sequence binds c-Jun/ATF2 heterodimers, and (as with c-Jun) ATF2 transactivating activity is increased by MAPK-catalyzed phosphorylation. [133] [134] [135] The interaction of calcineurin signaling pathways with MAPK pathways in hypertrophy is thus a distinct possibility (Figure 2 ). In addition, there are already examples of interaction of [Ca 2ϩ ] i with the ERK and JNK cascades in myocytes, 12, 136, 137 and a recent article has even suggested that the PKC3 Ras3 Raf3 MKK1/-23 ERK pathway may induce changes in Ca 2ϩ transients similar to those seen in myocardial hypertrophy and heart failure. 138 The mechanisms of these interactions remain relatively ill defined.
Might CsA and FK-506 Be Used to Treat Cardiac Hypertrophy and Heart Failure?
CsA has been reported to diminish the hypertrophy or dilated cardiomyopathy seen in 3 transgenic models involving mutations in myofibrillar proteins. 139 In addition, prophylactic administration of CsA inhibited the development of cardiac hypertrophy after suprarenal banding of the abdominal aorta in the rat. 139 In contrast, CsA does not prevent the cardiac hypertrophy induced by cardiospecific expression of an activated retinoic acid receptor, 139 implying that some forms of myocardial hypertrophy may be mediated by calcineurinindependent signaling pathways. However, 2 separate groups have subsequently been unable to detect any inhibitory effect of CsA or FK-506 on pressure-overload hypertrophy induced by constriction of the abdominal aorta in the rat 140 or the transverse aorta in the mouse. 141 Although these differences may be attributable to variations in experimental technique or to the time course of hypertrophy in pressure-overload models, 142 they do indicate that the involvement of calcineurin in hypertrophy in vivo has not been unambiguously established. More importantly, from the point of view of therapy, it is not clear whether administration of CsA during the "decompensated" phase of hypertrophy/heart failure (rather than prophylactic administration) is beneficial.
CsA is a relatively toxic drug that is used clinically to counteract rejection after transplantation. In addition to problems of immunosuppression (increased opportunistic infection and skin malignancies), the drug is nephrotoxic, and this may be caused by its interference with the calcineurindependent regulation of convoluted tubule Na ϩ /K ϩ -ATPase. 143 Its use is also associated with hypertension (possibly because of the nephrotoxic side effects involving renal vasoconstriction 144 ), neural effects (tremor and fits), hepatotoxicity, and gingival hypertrophy/hyperplasia. A number of studies in transplant patients have examined the association of cardiac hypertrophy with the use of CsA. Although some studies have failed to detect a convincing association (eg, Reference 145), others have shown that CsA may actually induce cardiac hypertrophy through its hypertensive side effects. 146, 147 In addition, at least 1 study has found that CsA has hypertrophic effects that are independent of its hypertensive effects. 148 Although FK-506 may cause fewer side effects, 144 it is more expensive than CsA. There is thus relatively little evidence that administration of immunosuppressants to human beings is antihypertrophic, and, in my view, it would be ill advised to administer them prophylactically.
Calcineurin and Specification of Skeletal Muscle Fiber Type
Transfection of calcineurin A(13398) into C2C12 myotubes increases transcription of slow fiber type-specific genes through NFATs and interacting transcription factors, and administration of CsA in intact rats increases the proportion of fast muscle fibers in the slow-twitch postural soleus muscle. 149 Characterization of muscle fiber composition in a suitable calcineurin A(13398) transgenic mouse is eagerly awaited. At first sight, the studies might seem irrelevant to myocardial disease. However, in a canine model of chronic heart failure, the proportion of slow-twitch fibers is decreased. 150 This could not be attributed to changes in capillary density or muscle fiber destruction. Similar changes in fiber type (combined with exercise intolerance) are seen in human heart failure, although here there may also be fiber loss and changes in capillary density (reviewed in Reference 151). A therapeutic regime that increases calcineurin activity and the content of slow-twitch fiber type in skeletal muscle might therefore be beneficial in heart failure patients. However, if calcineurin is involved in cardiac hypertrophy, such a regimen could be detrimental to the heart.
Do Derangements in Excitation-Contraction
Coupling Contribute to Cardiac Hypertrophy? [Ca 2ϩ ] i uptake and release are of major importance in the regulation of excitation-contraction coupling in the cardiac myocyte (reviewed in Reference 152), and (as originally shown by Gwathmey et al 153, 154 ) altered Ca 2ϩ "handling" is frequently encountered in hypertrophy and heart failure (reviewed in References 4 and 5 126 with calcineurin and CaM kinase II suggested as possible targets. The excitation-contraction characteristics of these myocytes have not been investigated. Cardiospecific overexpression of calsequestrin also induces hypertrophy. 29, 156 Myocytes from these mice show reduced CICR from the SR, increased storage of Ca 2ϩ in the SR, and depressed contractility. In contrast, the phospholamban knockout mouse shows positive inotropism and lusitropism (presumably because of release of the phospholamban-mediated inhibition of SERCA2 activity), but hearts are not hypertrophied. 157 Equally, overexpression of SERCA2 increases cardiac contraction and relaxation but does not cause hypertrophy. 28 However, reductions in cytoplasmic Ca 2ϩ concentrations do not appear to account for the hypertrophy and hyperplasia seen in the CaM transgenic mice, since overexpression of a mutant CaM that binds Ca 2ϩ normally but is defective in signaling to CaM targets/ effectors does not induce growth responses. 126 Obviously, it would be desirable to characterize Ca 2ϩ handling in all of these transgenic models under uniform conditions, but it is unlikely that this will ever be achieved.
Is there any evidence of interaction between calcineurin, the immunophilins, and proteins involved in excitationcontraction coupling? It is believed that FKBP12 interacts with RyR1, whereas the closely related protein FKBP12.6 interacts with cardiac RyR2 (reviewed in Reference 158) . FKBPs may mediate anchoring of calcineurin to the RyR, and this interaction may be involved in the regulation of channel activity through phosphorylation/dephosphorylation (reviewed in Reference 94). FK-506 disrupts this interaction. Interestingly, single RyR2 opening probability was increased in transgenic FKBP12 knockout mice, 159 although it is not clear whether increased RyR2 opening results from the absence of FKBP12 alone or the (presumed) absence of interaction of RyR2 with calcineurin. Although the FKBP12 knockout was frequently embryonically lethal, with mice displaying severe cardiac defects, 1 mouse that survived to adulthood showed signs of heart failure and cardiomyopathy.
In addition to release through the RyR, release of [Ca 2ϩ ] i from stores in the endoplasmic reticulum is regulated by the InsP 3 receptor (InsP 3 R), which is closely related to the RyR. Although the InsP 3 R was initially thought to be of little importance in the cardiac myocyte (and this is probably true for regulation of contraction), more detailed studies have established the presence of InsP 3 R species in cardiac myocytes, and at least in the ferret myocyte, the type 2 InsP 3 R predominates. 160 FKBP12 interacts with the InsP 3 R1 subtype, but it is not known whether InsP 3 R2 (or the InsP 3 R3) interacts with FKBP. However, the amino acid residues thought to be most important in binding of FKBP to InsP 3 R are conserved. 161 These results suggest that chronic activation of calcineurin could perturb Ca 2ϩ handling, and, if these perturbations led to defects in contraction, hypertrophy might indirectly ensue.
Mitochondrial Permeability Transition (MPT) Pore, Calcineurin, and Cell Necrosis/Apoptosis
Massive influx of [Ca 2ϩ ] o has long been known to be associated with death of the cardiac myocyte, a highly aerobic cell containing abundant mitochondria. The MPT is a phenomenon that leads to increased mitochondrial membrane permeability and collapse of the inner mitochondrial membrane electrochemical gradient (vital for regeneration of ATP from ADP and P i ). It can be attributed to the opening of nonspecific high-conductance pores (MPT pores) in the inner mitochondrial membrane that allow passage of small molecules of Յ1.5 kDa (reviewed in References 162 through 164). The structure of the MPT pore is not understood, but it is associated with inner-membrane adenine nucleotide translocase, 165 which exchanges intramitochondrial ATP for cytoplasmic ADP. In the heart, opening of the MPT pore is increased by oxidative stress and adenine nucleotide depletion, conditions that are encountered during ischemia/reperfusion. These situations enhance the sensitivity of the pore to Ca 2ϩ and increase binding of mitochondrial matrix cyclophilin to the mitochondrial membrane in a CsA-sensitive manner. Indeed, administration of CsA preserves mitochondrial integrity and cardiac function under adverse conditions (see, eg, References 166 through 168; reviewed in Reference 162), possibly through inhibition of MPT pore opening.
Mitochondrial permeability is intimately related to necrosis and to the mitochondrial pathway of apoptosis (reviewed in References 162 through 164). Apoptosis of the cardiac myocyte (reviewed in References 169 and 170) is an area arousing a great deal of interest currently because of the putative role of the process in the development of heart failure. In the mitochondrial pathway of apoptosis, release of cytochrome c from mitochondria allows formation of a complex between cytochrome c, apoptotic protease activating factor 1, ATP/dATP, and procaspase 9. This causes aggregation of procaspase 9 and its activation through cleavage to produce active caspase 9, which in turn leads to activation of caspases 3, 6, and 7. These caspases then cleave key substrates, leading to apoptosis. The mitochondrial pathway of apoptosis is inhibited by antiapoptotic members of the Bcl-2 family (Bcl-2 itself and Bcl-X L ) and is promoted by proapoptotic Bcl-2 family members (Bax and Bad). Although it does not directly allow escape of cytochrome c as such, opening of the MPT pore may be an initiating event in the mitochondrial apoptotic pathway. However, apoptotic situations involving the mitochondrial pathway that do not involve the MPT pore have been identified, and these may be related to the ability of proteins such as Bax to form membrane channels/pores.
Expression of wild-type calcineurin A and B, or of constitutively activated calcineurin A, promotes apoptosis in BHK cells (particularly in association with Ca 2ϩ influx), and this could be opposed by coexpression of Bcl-2, 171 with which calcineurin interacts. 172 Although calcineurin bound to Bcl-2 retains its phosphatase activity, formation of the complex is thought to localize calcineurin to an intracellular membrane fraction at which it is unable to dephosphorylate NFATs. 172 In agreement with the foregoing, CsA and FK-506 inhibit apoptosis in a lymphoma cell line. 173 The mechanisms underlying the proapoptotic function of calcineurin have not been elucidated, although it is possible that dephosphorylation of Bad (Bad phosphorylation suppresses its proapoptotic function) could be important (reviewed in Reference 174) .
The preceding discussion suggests that some of the findings of Molkentin et al 14 could be related to the ability of calcineurin and the MPT pore to promote cell death/apoptosis. Postmortem hearts from calcineurin A(13398) transgenic mice showed signs of heart failure with dilatation and gross fibrosis. 14 Although the subject of much current debate, it has been suggested that human heart failure might be associated with apoptosis of the cardiac myocyte. 175, 176 Hypothetically, it could be argued that cardiospecific activation of calcineurin could promote apoptosis of myocytes, and it is this that leads to heart failure. CsA could prevent calcineurindependent apoptosis and the MPT. Indeed, in endothelial cells, CsA inhibits apoptosis by preventing mitochondrial efflux of cytochrome c. 177 One major problem with this hypothesis is that cardiomyocytic expression of NFAT3⌬317 leads to hypertrophy. 14 However, it is not clear whether the phenotype was as severe as in the calcineurin A(13398) transgenic animals, and NFATs are known to play a role in cardiac development. 127 More details of the NFAT3⌬317 model would be of interest.
General Comments and Future Directions
In addition to more detailed work in experimental animals, there is clearly a need to extend the work to humans. This is never easy, as prospective studies are not feasible. By the time samples of hypertrophied myocardium are available, the initiating signals may no longer be detectable. It is not clear whether the calcineurin pathway can stimulate protein synthesis in myocytes, and this should be examined. Several of the studies cited in this review have made use of transgenic mouse models, and some of the problems associated with this approach have been discussed. Inducible transgenic animals may help. In some transgenic mice, cardiac defects and disturbances in excitation-contraction coupling coexist. By interacting with RyR2 or other proteins, calcineurin A(13398) might perturb excitation-contraction coupling, indirectly leading to cardiac hypertrophy and heart failure. The effects of calcineurin A(13398) on Ca 2ϩ transients and contractility in transiently transfected myocytes or in myocytes from the calcineurin A(13398) transgenic animal would be of interest. Calcineurin and the immunophilins also interact with signaling systems that have not been discussed here. These include the transforming growth factor ␤ receptor (reviewed in Reference 178) and the protein kinase A anchoring proteins, which are involved in targeting protein kinase A to specific cellular locations (reviewed in Reference 179) . Given the importance of protein kinase A in regulating myocardial contractility through modulation of L-type Ca 2ϩ channel activity (reviewed in Reference 4), this is another potential point of interaction between calcineurin and Ca 2ϩ handling.
It is unlikely that a single signaling pathway is responsible for the overall hypertrophic response. Interaction of the calcineurin pathway with other signaling pathways, such as the MAPK pathways, should be examined. Intuitively, in the absence of more complex regulation, these 2 pathways would
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April 2, 1999 641 appear to be in opposition, 1 (MAPKs) promoting phosphorylation and the other (calcineurin) promoting dephosphorylation. Examination of MAPK involvement in the regulation of the transactivating activity of transcription factors that associate with NFAT would be worthwhile, and in this regard, GATA4 contains 1 strong MAPK recognition sequence at residues 102 to 105 (Pro-Val-Ser-Pro), as well as several (Ser/Thr)-Pro sequences. 106 With these thoughts in mind, I suggest that the involvement of calcineurin in myocardial hypertrophy has not been unambiguously established and that there is life after calcineurin for those of us working in this area.
Note Added in Proof
Transgenic mice cardiospecifically expressing constitutively activated G␣ q develop cardiac hypertrophy, then dilated cardiomyopathy and heart failure. 202 The effects of CsA in this model were equivocal. It did not diminish hypertrophy when heart weight was expressed relative to body weight, but did so when heart weight was expressed relative to tibial length. There was also an indication that CsA prevented some (but not all) of the changes in gene expression associated with hypertrophy in this model.
